GlassScriptPhysician profile
Staci Damiani
NPI 1043753502
$11,638.65
in general payments reported to CMS, 2019-2025
58 companies · $2,275 in 2025
The $2,275 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,488 · 2022: $2,766 · 2023: $1,790 · 2024: $2,319 · 2025: $2,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,384.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,579.08 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,451.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,226.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,085.60 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $681.61 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $641.52 | 2021-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $545.18 | 2021-2025 | Xifaxan |
| Pfizer INC. | $397.14 | 2021-2025 | |
| Antares Pharma, INC. | $349.21 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $292.15 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $250.54 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $248.08 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $208.13 | 2021-2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $205.07 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $204.73 | 2021-2025 | Repatha, Otezla, Otezla |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Damiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.